Efforts to Control Prescription Drug Pricing Harm Collaborative Work to Advance Patient Care with Health Innovations
By: Colorado BioScience Association Date: 09/18/2023
Elyse Blazevich, President & CEO, Colorado BioScience Association Colorado’s life sciences community and our state leaders share an unwavering commitment to improving patient lives and making sure...
Learn MoreWeekly Policy Blog: FDA Guidances on 510(k) Submissions; Actuarial Review of Biomarker Testing Coverage Bill
By: Colorado BioScience Association Date: 09/11/2023
FDA Issues Three Guidances on Premarket Notification [510(k)] Program On September 7, 2023, the U.S. Food and Drug Administration’s (FDA’s) Center for Devices and Radiological Health (CDRH) issu...
Learn MoreWeekly Policy Blog: CMS Announces Drugs Subject to Price Controls Under the IRA
By: Colorado BioScience Association Date: 09/05/2023
On August 29, 2023, the Centers for Medicare and Medicaid Services (CMS) announced the first ten prescription drugs that will be subject to price controls in Medicare under the Inflation Reduction Act...
Learn MoreWeekly Policy Blog: CBSA and Partners Provide Recommendations to Improve CMS’ Transitional Coverage for Emerging Technologies (TCET) Proposal
By: Colorado BioScience Association Date: 08/28/2023
CBSA advocates for policies that improve patient access to life-saving novel technologies. This week, CBSA signed on to a letter responding to the long-awaited proposed Transitional Coverage for Emerg...
Learn MoreWeekly Policy Blog: PDAB Releases Stakeholder Engagement Guide on Affordability Review Process
By: Colorado BioScience Association Date: 08/14/2023
As the Colorado Prescription Drug Affordability Board (PDAB) begins affordability reviews of the five prescription drugs selected earlier this month, it is reaching out to stakeholders to request thei...
Learn MoreWeekly Policy Blog: PDAB Selects Drugs for Affordability Reviews
By: Colorado BioScience Association Date: 08/07/2023
On Friday, August 4, the Colorado Prescription Drug Affordability Board (PDAB) selected five drugs for affordability reviews: Enbrel, Genvoya, Cosentyx, Stelara, and Trikafta. PDAB staff plan to begin...
Learn MoreWeekly Policy Blog: Congressional Activity Before August Recess
By: Colorado BioScience Association Date: 07/31/2023
Congress moved forward with its efforts to address drug shortages, drug pricing, pharmacy benefit managers (PBMs), and transparency ahead of the August recess. This policy post covers the discussion d...
Learn MoreWeekly Policy Blog: PAHPA Reauthorization Advances Without Government Price Fixing
By: Colorado BioScience Association Date: 07/24/2023
Congress took important action on pandemic preparedness last week, advancing the Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization bills in both the Senate and the House ahead of its e...
Learn MoreWeekly Policy Blog: Drug Pricing and Affordability Update
By: Colorado BioScience Association Date: 07/17/2023
Drug pricing and affordability continue to be key issues at both the state and federal levels as new legislation is considered and implementation of legislation that has already passed is underway....
Learn MoreWeekly Policy Blog: Ethylene Oxide – EPA’s Proposed Rules
By: Colorado BioScience Association Date: 07/10/2023
Ethylene Oxide (EtO or EO) is a colorless gas used commercially in a wide variety of ways. It is one of the most common and proven ways to sterilize medical devices. EtO’s proven effectiveness means t...
Learn More